Navigation Links
TPI to Host Third Quarter Fiscal Year 2013 Earnings Conference Call on Wednesday, May 15, 2013 at 9 a.m. ET
Date:5/5/2013

CHENGDU, China, May 5, 2013 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), today announced that the earnings conference call for the third quarter of fiscal year 2013 ending March 31, 2013 to be held at 9:00 a.m. ET on Wednesday, May 15th, 2013.

Interested parties may access the call by dialingToll free:

1-877-941-1427International: 

1-480-629-9664The conference ID is 4617492. It is advisable to dial in approximately 5 minutes prior to the start of the call.

A replay will be available by calling

Toll free:

1-877-870-5176International:

1-858-384-5517From:

05/15/13 @ 12:00 pm E.T.To:

05/29/13 @ 11:59 pm E.T.Replay Pin Number:

4617492This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at the following link: http://public.viavid.com/index.php?id=104577

About TPIHeadquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list (EDL) of China. TPI's pipeline targets various high incidence healthcare indications. For more information about TPI, please visit: http://www.tianyinpharma.com

Safe Harbor StatementThe Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit: http://www.tianyinpharma.com, or email: ir@tpi.asia

Tel:
+86-28-8551-6696 (Chengdu, China)
+86-134-3655-0011 (China)

Address:

Tianyin Pharmaceutical
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China


'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardica Announces Fiscal 2013 Third Quarter Financial Results
2. Hill-Rom Reports Fiscal Second Quarter Adjusted Earnings Per Share In Line With Expectations; Provides Third Quarter And Updated Full-Year Financial Outlook
3. Perrigo Company To Release Third Quarter Fiscal Year 2013 Results On May 7, 2013
4. Freudenberg Reports Third Year of Sales Growth in 2012
5. Accuray Incorporated to Report Financial Results for Third Quarter Fiscal 2013
6. Cardica to Announce Fiscal 2013 Third Quarter Financial Results On Tuesday, April 30, 2013
7. CareFusion to Report Third Quarter Fiscal 2013 Results on May 9
8. Cardinal Health To Release Third-Quarter Results For Fiscal Year 2013 On May 2
9. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
10. ResMed Announces Conference Call And Webcast To Discuss Third Quarter 2013 Results
11. Third FDA Clearance for Revolutionary Simbionix Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... 2017  Bayer announced today that the latest research ... at the 53 rd Annual Meeting of the ... 2-6 in Chicago . ... colorectal, liver and thyroid cancers, as well as lymphomas, ... CHRONOS-1 trial of copanlisib in patients with relapsed or ...
(Date:5/15/2017)... May 15, 2017 Enterin Inc., a privately-held CNS ... developing novel compounds to treat Parkinson,s disease (PD), has enrolled ... a Phase 1/2a randomized, controlled, multicenter study involving patients with ... enroll 50 patients over a 9-to-12-month period. The first stage ... patients with PD. Participating sites include Denver ...
(Date:5/11/2017)... , May 11, 2017  Thornhill Research ... has been awarded an $8,049,024 USD five-year, firm-fixed-priced, ... through the Canadian Commercial Corporation (CCC) ( ... Anesthesia Systems to administer general anesthesia to patients ... "The US Marine Corps have been ...
Breaking Medicine Technology:
(Date:5/23/2017)... San Francisco, California (PRWEB) , ... May 23, 2017 , ... ... released results of its new survey in an infographic on the current state of ... 900 U.S. respondents, familiar with anxiety, was conducted in April 2017 and benchmarked general ...
(Date:5/22/2017)... ... 2017 , ... The American Academy of Thermology ... and clinical application of medical infrared imaging, has announced two new educational offerings ... services. , The first new educational offering is an online self-directed Physician Member ...
(Date:5/22/2017)... NC (PRWEB) , ... May 22, 2017 , ... ... Matthews Periodontics, is now welcoming new patients with periodontal plastic surgery treatments, including ... from a general dentist. Dr. Green provides these esthetic and functional procedures to ...
(Date:5/22/2017)... ... ... An inventor from Columbia, S.C., wants to offer people with manual disabilities a ... firework accident, so she couldn’t grip a pen properly," he said. "This inspired me ... created a prototype for the HELPEN HAND, a special pen that enables a person ...
(Date:5/22/2017)... ... May 22, 2017 , ... Galena, Alaska, has a population of less than ... when it was targeted to build a nuclear plant by the TOSHIBA Corporation. , ... Marvin L. Yoder describes the journey to get power to his small town, off ...
Breaking Medicine News(10 mins):